YFYngve Falck-Ytter

Yngve Falck-Ytter

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yngve Falck-Ytter has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment

    by Daniel J. Buysse, J. Todd Arnedt, Luis Buenaver, Judy L. Chang, Julio Fernandez-Mendoza, Salma I. Patel, Eric S. Zhou, Yngve Falck-Ytter, Suzanne Hyer, Uzma Kazmi, et al.

    Introduction This systematic review provides supporting evidence for the accompanying clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Methods The American Academy of Sleep Medicine (AASM) commissioned a task force (TF) of sleep medicine experts. A systematic review was conducted to identify studies that compared the use of combination treatment (behavioral-psychological treatment used concurrently with pharmacological treatment) to therapy with behavioral-psychological or pharmacological treatments. Statistical analyses were performed to determine the clinical meaningfulness of using various interventions to treat chronic insomnia in adults. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence for making recommendations. Results The literature search resulted in 1,179 articles, out of which 15 articles provided data suitable for meta-analyses. The TF provided a detailed summary of the evidence along with the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations.


  • Top Cited Papers
    Open Access

    Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline

    by Daniel J. Buysse, J. Todd Arnedt, Luis Buenaver, Judy L. Chang, Julio Fernandez-Mendoza, Salma I. Patel, Eric S. Zhou, Yngve Falck-Ytter, Suzanne Hyer, Uzma Kazmi, et al.

    This guideline establishes clinical practice recommendations for combination treatment of chronic insomnia disorder in adults, defined here as treatment with cognitive-behavioral therapy for insomnia (CBT-I) started concurrently with pharmacotherapy. The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths to those recommendations based on a systematic review of the literature and an assessment of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process. The task force provided a summary of the relevant literature, the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations. The following recommendations are intended as a guide for clinicians on the use of combination treatment for chronic insomnia disorder in adults. Each recommendation statement is assigned a strength (“Strong” or “Conditional”). A “Strong” recommendation (i.e., “We recommend…”) is one that clinicians should follow under most circumstances. A “Conditional” recommendation (i.e., “We suggest…”) is one that requires that the clinician use clinical knowledge and experience and strongly consider the patient’s values and preferences to determine the best course of action. One recommendation includes a remark that provides additional context to guide clinicians with implementation of this recommendation. Conditional recommendation for: 1. In adults with chronic insomnia disorder, the AASM suggests the use of combination treatment with CBT-I plus insomnia medication over insomnia medication alone. (Conditional recommendation, low certainty of evidence). Conditional recommendation against: 2. In adults with chronic insomnia disorder, the AASM suggests against the use of combination treatment of CBT-I plus insomnia medication over CBT-I alone. (Conditional recommendation, low certainty of evidence). Remark: Patients who place higher value on increasing total sleep time early in the course of treatment, and/or who place lower value on reducing daytime symptoms with treatment, may reasonably select combination treatment versus CBT-I alone.


  • Open Access

    What Constitutes a High‐Quality Guideline: Exploring Consumers' Views

    by Alberto Balduzzi, Francesco Maria Carrano, Yngve Falck‐Ytter, Haluk Tarik Kani, Iris Levink, Yasuko Maeda, Irene Marafini, Adele Sayers, EAES/ECCO/ESCP/ESGAR/ESGE/ESPGHAN/UEG/UEGJ Quality of Guideline Collaborative Group

    Introduction: Clinical guidelines are a cornerstone of evidence‐based medicine. Little is known about clinicians' knowledge of guideline development and how they perceive guideline quality.Methods: A survey protocol was designed according to the CHERRIES (improving the quality of web surveys: the Checklist for Reporting Results of Internet E‐Surveys) checklist. The survey explored three main aspects: high‐quality markers of guidelines, knowledge of guideline development, and areas for improvement. The survey was conducted by contacting UEG and affiliated societies by email and via social media. All valid answers to each question were counted.Results: A total of 585 participants responded during the 3‐month period. Some 65.8% were aged between 30 and 60 years, and 75.4% were doctors. The most important perceived quality indicators within a guideline were ‘clear and actionable recommendations (97%)’, followed by ‘based on systematic literature review’ (96%), and ‘transparent methodology’ (90%). 230 (39.3%) respondents were previously involved in clinical guideline development. However, the experience of working with a methodologist (18.8%) and using well‐established guideline checklists (AGREE‐II [21.0%]), RIGHT (Reporting Items for Practice guidelines in HealThcare) (9.9%) were limited. Just under half of the responders (289, 49.4%) were familiar with the GRADE methodology. Apps (78.5%), webinars (73.8%), and short videos (68.2%) were popular tools to access clinical guidelines. Over 90% of responders stated that the reputation of the journal (92%) and the name of the society involved in guideline development (91%) were important. Two‐thirds of the responders preferred to see abridged versions of guidelines and 69.2% preferred freely accessible or open access guidelines.Conclusion: Consumers are keen to read clear and actionable guidelines that are developed transparently. There is a gap in guideline development knowledge. Initiatives by medical journals and professional societies are important to ensure the development of accessible and robust clinical guidelines.


  • Open Access

    During HCV DAA Therapy Plasma Mip1B, IP10, and miRNA Profile Are Distinctly Associated with Subsequent Diagnosis of Hepatocellular Carcinoma: A Pilot Study

    by Sofi Damjanovska, Hawwa Alao, Elizabeth Zebrowski, Corinne Kowal, Lenche Kostadinova, Perica Davitkov, Yngve Falck-Ytter, Carey L. Shive, Michael Cartwright, Brian Richardson, et al.

    Background: Hepatitis C virus (HCV) therapy lowers risk of hepatocellular carcinoma (HCC). Little is known about factors driving/preceding HCC in treated persons. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) regulate host response and pathogenesis of disease. We investigated plasma levels of these RNAs and select serum markers before, during, and after HCV therapy, preceding HCC. Methods: Of 187 DAA treated HCV patients where therapy oriented longitudinal sampling was performed at a time without HCC diagnosis, 9 were subsequently diagnosed with HCC within 2 years of therapy. They were matched with 7 patients not diagnosed with HCC over the same time period. RNASeq was performed on plasma, and serum was assessed for biomarkers of inflammation by ELISA. Results: HCC diagnosis was 19 months (6–28) after therapy start in the HCC group. 73 and 63 miRs were differentially expressed at baseline (before DAA therapy) and 12 weeks after DAA therapy comparing HCC and non-HCC groups. Several lncRNA- showed differential expression as well. Several miRNA suppressors of cancer-related pathways, lncRNA- and mRNA-derived stabilized short RNAs were consistently absent in the plasma of patients who developed HCC. Serum IP10, and MCP-1 level was higher in the HCC group 12 weeks after therapy, and distinct miRNAs correlated with IP10 and MCP-1. Finally, in a focused analysis of 8 miRNAs best associated with HCC we observed expression of mi576 and mi-5189 correlation with expression of a select group of PBMC mRNA. Conclusions: These results are consistent with complex interplay between RNA-mediated host immune regulation and cancer suppression, strikingly skewed 12 weeks following therapy, prior to HCC diagnosis.


  • An International Needs Assessment Survey of Guideline Developers Demonstrates Variability in Resources and Challenges to Collaboration between Organizations

    by Shahnaz Sultan, Madelin R. Siedler, Rebecca L. Morgan, Toju Ogunremi, Philipp Dahm, Lisa A. Fatheree, Thomas S. D. Getchius, Pamela K. Ginex, Priya Jakhmola, Emma McFarlane, et al.

    Background The development of rigorous, high-quality clinical guidelines increases the need for resources and skilled personnel within guideline-producing organizations. While collaboration between organizations provides a unique opportunity to pool resources and save time and effort, the collaboration presents its own unique challenges. Objective To assess the perceived needs and current challenges of guideline producers worldwide related to guideline development and collaboration efforts. Design Survey questions were developed by the Guidelines International Network and the US GRADE Network, pilot-tested among attendees of a guideline development workshop, and disseminated electronically using convenience and snowball sampling methods. Participants A total of 171 respondents representing 30 countries and more than 112 unique organizations were included in this analysis. Main Measures The survey included free-response, multiple-choice, and seven-point Likert-scale questions. Questions assessed respondents’ perceived value of guidelines, resource availability and needs, guideline development processes, and collaboration efforts of their organization. Key Results Time required to develop high-quality systematic reviews and guidelines was the most relevant need (median=7; IQR=5.5–7). In-house resources to conduct literature searches (median=4; IQR=3–6) and the resources to develop rigorous guidelines rapidly (median=4; IQR=2–5) were perceived as the least available resources. Difficulties reconciling differences in guideline methodology (median=6; IQR=4–7) and the time required to establish collaborative agreements (median=6; IQR=5–6) were the most relevant barriers to collaboration between organizations. Results also indicated a general need for improvement in conflict of interest (COI) disclosure policies. Conclusion The survey identified organizational challenges in supporting rigorous guideline development, including the time, resources, and personnel required. Connecting guideline developers to existing databases of high-quality systematic reviews and the use of freely available online platforms may facilitate guideline development. Guideline-producing organizations may also consider allocating resources to hiring or training personnel with expertise in systematic review methodologies or utilizing resources more effectively by establishing collaborations with other organizations.


  • Open Access

    Corrigendum to GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011;64:1283–1293

    by Gordon Guyatt, Andrew D. Oxman, Regina Kunz, Jan Brozek, Pablo Alonso-Coello, David Rind, P.J. Devereaux, Victor M. Montori, Bo Freyschuss, Gunn Vist, et al.


  • Open Access

    CD56bright NK IL-7Rα expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections

    by Chelsey J. Judge, Lenche Kostadinova, Kenneth E Sherman, Adeel A Butt, Yngve Falck-Ytter, Nicholas T. Funderburg, Alan L. Landay, Michael M. Lederman, Scott F. Sieg, Johan K. Sandberg, et al.

    Several lines of evidence support the concept that NK cells play an important role in control of hepatitis C virus (HCV) infection via cytokine secretion and cytotoxicity. IL-7 is a homeostatic cytokine with a role in T cell development, activation, proliferation, and cytokine secretion. The IL-7Rα chain [cluster of differentiation (CD)127] is expressed on NK cells, with greatest abundance on the CD56brightCD16dim/− (CD56bright) subset. Here, we measured CD127 expression on CD56bright, CD56dimCD16+ (CD56dim), or CD56negCD16+ (CD56neg) NK cell subsets of 25 uninfected donors (UD); 34 chronic HCV-infected, treatment-naiüve; 25 HIV-infected, virally suppressed on antiretroviral therapy (ART); and 42 HCV–HIV-coinfected subjects on ART. Interestingly, CD127 expression on CD56bright NK cells negatively correlated with HCV plasma levels in HCV monoinfection and HCV–HIV coinfection. IL-7 induced CD69 expression, as well as IFN-γ production, in CD56bright NK cells and also enhanced the IFN-α-induced CD69 expression on these cells. The latter was impaired in HIV infection. Furthermore, IL-7 induced B cell lymphoma 2 (BCL-2) expression and cell cycling of CD56bright NK cells, and this effect was impaired in HCV- and HIV-infected subjects. Whereas IL-7-stimulated CD56bright NK cell degranulation appeared intact in all cohorts, we observed impaired IL-7-activated NK cell cytolytic function in HCV- and HIV-infected subjects. Finally, IL-7-induced phosphorylation of STAT-5 (pSTAT-5) signaling was impaired in NK cells of subjects with chronic viral infection, and this was reversible upon 6 mo of viral suppression with IFN-free HCV therapy. These results implicate that IL-7-dependent NK cell activation and effector function may be other host immune surveillance mechanisms that are impaired in viral infections.


  • Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel

    by Justin R Cuschieri, Paul Drawz, Yngve Falck‐Ytter, Richard C K Wong

    Objective: Our aim was to identify risk factors for acute gastrointestinal (GI) bleeding in patients with myocardial infarction (MI) who were prescribed clopidogrel following hospital discharge.Methods: Data were collected retrospectively from patients treated in Veteran Affairs hospitals in Ohio, USA, from 2001 to 2008 with a primary diagnosis of MI (International Classification of Diseases, 9th Revision) and a prescription for clopidogrel filled within 48 h of discharge. Primary outcome was acute GI bleeding after discharge.Results: Acute GI bleeding occurred in 107 of 3218 patients. Bleeding occurred in those who were elder (66.2 vs 62.4 years, P = 0.0002), had lower glomerular filtration rate (74 vs 81 mL/min, P = 0.024), had filled prescription for warfarin (15.9% vs 6.9%, P = 0.0004), diagnosed as atrial fibrillation (20.6% vs 11.1%, P = 0.003), chronic liver (5.6% vs 2.2%, P = 0.018) or kidney disease (29.0% vs 19.4%, P = 0.016). A risk model and GI bleed risk score were developed and showed that patients with age >65 years, use of warfarin, the presence of chronic liver or kidney disease were at increased risk for GI bleeding.Conclusions: Veterans patients of advanced age, using warfarin and with chronic liver and kidney disease may be at increased risk of GI bleeding when prescribed clopidogrel following MI. A scoring system may help to identify patients at high risk for GI bleeding.